SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Cemal Cingi, Nuray Bayar Muluk, Deniz Hanci, Seckin Ulusoy, Fezan Sahin, Updating the role played by immunotherapy for allergic rhinitis: meta-analysis, International Forum of Allergy & Rhinology, 2015, 5, 2
  2. 2
    Amelia Licari, Alessia Marseglia, Silvia Caimmi, Riccardo Castagnoli, Thomas Foiadelli, Salvatore Barberi, Gian Luigi Marseglia, Omalizumab in Children, Pediatric Drugs, 2014, 16, 6, 491

    CrossRef

  3. 3
    Hsing-Mao Chu, Jon Wright, Yueh-Hsuan Chan, Chien-Jen Lin, Tse Wen Chang, Carmay Lim, Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations, Nature Communications, 2014, 5,

    CrossRef

  4. 4
    Désirée Larenas-Linnemann, Ulrich Wahn, Matthias Kopp, Use of omalizumab to improve desensitization safety in allergen immunotherapy, Journal of Allergy and Clinical Immunology, 2014, 133, 3, 937

    CrossRef

  5. 5
    K Suresh Babu, Riccardo Polosa, Jaymin B Morjaria, Anti-IgE – emerging opportunities for Omalizumab, Expert Opinion on Biological Therapy, 2013, 13, 5, 765

    CrossRef

  6. 6
    W. S. Lexmond, M. Pardo, K. Rooney, J. A. Goettel, S. B. Snapper, E. H. Yen, E. Dehlink, S. Nurko, E. Fiebiger, Elevated levels of leukotriene C4 synthase mRNA distinguish a subpopulation of eosinophilic oesophagitis patients, Clinical & Experimental Allergy, 2013, 43, 8
  7. 7
    Olympia A. Tsilochristou, Nikolaos Douladiris, Michael Makris, Nikolaos G. Papadopoulos, Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?, Pediatric Drugs, 2013, 15, 6, 431

    CrossRef

  8. 8
    Yasuo Shimizu, Kunio Dobashi, CC-Chemokine CCL15 Expression and Possible Implications for the Pathogenesis of IgE-Related Severe Asthma, Mediators of Inflammation, 2012, 2012, 1

    CrossRef

  9. 9
    Kari C. Nadeau, Arunima Kohli, Shuba Iyengar, Rosemarie H. DeKruyff, Dale T. Umetsu, Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy, Immunology and Allergy Clinics of North America, 2012, 32, 1, 111

    CrossRef

  10. 10
    Matthias Volkmar Kopp, Omalizumab: Anti-IgE Therapy in Allergy, Current Allergy and Asthma Reports, 2011, 11, 2, 101

    CrossRef

  11. 11
    B. Wedi, F. Ruëff, Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie, Der Hautarzt, 2011, 62, 9, 663

    CrossRef

  12. 12
    M. V. Kopp, Role of immunmodulators in allergen-specific immunotherapy, Allergy, 2011, 66, 6
  13. 13
    Wolfgang Kamin, Matthias Volkmar Kopp, Frank Erdnuess, Uwe Schauer, Stefan Zielen, Ulrich Wahn, Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously, Pediatric Allergy and Immunology, 2010, 21, 1-Part-II
  14. 14
    J. M. Martínez-Gómez, P. Johansen, H. Rose, M. Steiner, G. Senti, C. Rhyner, R. Crameri, T. M. Kündig, Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy, Allergy, 2009, 64, 1
  15. 15
    Kimihiro Okubo, Toshikazu Nagakura, Anti-IgE Antibody Therapy for Japanese Cedar Pollinosis: Omalizumab Update, Allergology International, 2008, 57, 3, 205

    CrossRef

  16. 16
    Roy Gerth van Wijk, When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies, Current Opinion in Allergy and Clinical Immunology, 2008, 8, 6, 565

    CrossRef

  17. 17
    LiteratureWatch, Pediatric Asthma, Allergy & Immunology, 2007, 20, 4, 269

    CrossRef